Advertisement

HQL

Abrdn Life Sciences Investors

Financial Services · USD

Set alert

Price alert · HQL

All alert types
18.44 USD -0.30 -1.60%
As of Oct 30, 2026 Extended hours 18.44 0.00%
Bid
18.39 × 200
Ask
18.44 × 700
18.25 Day range 18.77
15.87 52-week range 22.67
YTD
+9.89%
1 year
+4.77%
Open
18.77
Prev close
18.74
Mkt cap
560.72M
Vol
86.55K
Avg vol
134.32K
EPS
6.64
P/E
2.78
Div yield
14.12%
More statistics
Low
18.25
High
18.77
Forward P/E
0.00
Beta
0.70
Short ratio
0.41
Inst. own
35.35%
Dividend
2.00
Ex-div date
Nov 20, 2024
50-d avg
14.47
200-d avg
14.34
1y target
0.00

2Y chart

Chart tools
Interval
HQL two-year price chart10.613.616.619.622.7Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
377.99M
Enterprise value
0
Trailing P/E
4.43
Forward P/E
0.00
PEG ratio
0.00
Price / sales
107.60
Price / book
0.84
EPS (TTM)
3.04
Beta
0.70
Dividend yield
14.12%
Payout ratio
54.61%
Profit margin
156.45%
Revenue (TTM)
3.51M
Revenue growth
7.00%
Free cash flow
0
Total cash
0
Total debt
0
Return on equity
1.28%
Shares outstanding
28.06M
Short % of float
0.00%
50-day average
14.47
200-day average
14.34

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Sector
Financial Services
Industry
Asset Management
Country
United States

News

Your note

Sign in to keep a note on HQL — it syncs with the Stock Master app.

Insider holders

HQL insider holders
InsiderRelationLatest transactionDateShares held
DIMARTINO ROSEDirectorPurchaseJul 15, 20241,000
GOETZ KATHLEENDirectorPurchaseApr 8, 20241,085
MAHER C WILLIAMDirectorPurchaseAug 22, 20240
OMSTEAD DANIEL RPresidentPurchaseSep 24, 2023197,518
REIT TODDDirectorPurchaseJan 1, 20241,000
SABA CAPITAL MANAGEMENT L PBeneficial Owner of more than 10% of a Class of SecurityPurchaseJun 25, 20240

Institution ownership

HQL institution ownership
Holder% heldSharesValueReported
Saba Capital Management, L.P.12.54%3,429,99146.20MSep 29, 2024
Penserra Capital Management LLC2.84%776,00210.45MSep 29, 2024
Morgan Stanley1.79%489,6876.60MSep 29, 2024
Karpus Management, Inc.1.71%468,5986.31MSep 29, 2024
SIT Investment Associates Inc1.52%417,0645.62MSep 29, 2024
Needham Investment Management, L.L.C.1.29%352,7194.75MSep 29, 2024

Fund ownership

HQL fund ownership
Holder% heldSharesValueReported
Amplify High Income ETF2.83%774,19810.43MSep 29, 2024
Exchange Listed Fds Tr-Saba Closed-End Funds ETF0.98%268,0883.61MAug 30, 2024
Saba Capital Income & Opportunities Fund II0.47%128,6011.73MJul 30, 2024
AQR Funds-AQR Diversified Arbitrage Fd0.31%84,4991.14MSep 29, 2024
Saba Capital Income & Opportunities Fd0.14%37,835509.64KJul 30, 2024
First Trust Income Opportunity ETF0.05%13,358179.93KOct 30, 2024
Advertisement